Luiza Reali Nazario

Has grant

University Medical Center Groningen
Country flagNetherlands

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

JAN KORNELIS DE COCK-STICHTING Foundation

Open Date:

Close Date:

Articles (7)

Year:

2026

Year:

2026

Year:

2026

Year:

2024

Introduction Bacterial infections are a major problem in medicine, and the rapid and accurate detection of such infections is essential for optimal patient outcome. Bacterial infections can be diagnosed by nuclear imaging, but most currently available modalities are unable to discriminate infection from sterile inflammation. Bacteria-targeted positron emission tomography (PET) tracers have the potential to overcome this hurdle. In the present study, we compared three 18 F-labelled PET tracers based on the clinically applied antibiotic vancomycin for targeted imaging of Gram-positive bacteria. Methods [ 18 F]FB-NHS and [ 18 F]BODIPY-FL-NHS were conjugated to vancomycin. The resulting conjugates, together with our previously developed [ 18 F]PQ-VE1-vancomycin, were tested for stability, lipophilicity, selective binding to Gram-positive bacteria, antimicrobial activity and biodistribution. For the first time, the pharmacokinetic properties of all three tracers were compared in healthy animals to identify potential binding sites. Results [ 18 F]FB-vancomycin, [ 18 F]BODIPY-FL-vancomycin, and [ 18 F]PQ-VE1-vancomycin were successfully synthesized with radiochemical yields of 11.7%, 2.6%, and 0.8%, respectively. [ 18 F]FB-vancomycin exhibited poor in vitro and in vivo stability and, accordingly, no bacterial binding. In contrast, [ 18 F]BODIPY-FL-vancomycin and [ 18 F]PQ-VE1-vancomycin showed strong and specific binding to Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), which was outcompeted by unlabeled vancomycin only at concentrations exceeding clinically relevant vancomycin blood levels. Biodistribution showed renal clearance of [ 18 F]PQ-VE1-vancomycin and [ 18 F]BODIPY-FL-vancomycin with low non-specific accumulation in muscles, fat and bones. Conclusion Here we present the synthesis and first evaluation of the vancomycin-based PET tracers [ 18 F]BODIPY-FL-vancomycin and [ 18 F]PQ-VE1-vancomycin for image-guided detection of Gram-positive bacteria. Our study paves the way towards real-time bacteria-targeted diagnosis of soft tissue and implant-associated infections that are oftentimes caused by Gram-positive bacteria, even after prophylactic treatment with vancomycin.

Year:

2024

Year:

2024

Year:

2024

Collaborators (6)

Janine Doorduin

University Medical Center Groningen

NETHERLANDS
View details

Marco Demaria

Scientific Staff

University Medical Center Groningen

NETHERLANDS
View details

Robert P Coppes

Scientific Staff

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details

Lara Barazzuol

Associate Professor

University Medical Center Groningen

NETHERLANDS
View details

Erik de Vries

full professor

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details

Nadja Simeth

Associate Professor

University of Göttingen

GERMANY
View details